Biomarker-oriented Study of Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2018
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Tremelimumab (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
- Focus Therapeutic Use
- 05 Sep 2018 Planned End Date changed from 1 Mar 2019 to 1 May 2020.
- 05 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 May 2020.
- 25 Feb 2017 Status changed from not yet recruiting to recruiting.